A new anti-inflammatory mechanism identified

Research Published October 25 2022
Open / close summary

The team “Plasticity and regeneration of myelin” co-directed by Brahim NAIT-OUMESMAR, Inserm Research Director at the Paris Brain Institute – in collaboration with Angela Giangrande’s team (IGBMC, Illkirch) has just demonstrated that the Gcm2 gene has a conserved function from flies to humans in the control of inflammation of the central nervous system. This work is published in Cell Reports.

The gcm gene

The gcm (glial cells missing) gene was initially identified in the fly Drosophila melanogaster as a key regulator of the determination of undifferentiated neural cells into glial cells of the nervous system. Thus, Drosophila in which this gene is inactivated show a complete absence of glial cells and an excess of neurons. In Drosophila, gcm is also required for the differentiation of hemocytes, cells related to macrophages in mammals.

RNAscope detection of Gcm2 expression (red) in microglia/macrophages (Cx3cr1, green) in a spinal cord demyelinating lesion.

 

An anti-inflammatory effect

In this study, the researchers showed that Gcm2 is expressed by microglial cells (the resident immune cells of the central nervous system), during brain aging in a mouse model, suggesting that the increased inflammation in the aged brain is partly due to these immune cells.

The study of mice in which the Gcm2 gene is inactivated showed a modification of the morphology of microglial cells associated with a pro-inflammatory profile, during aging or in response to myelin lesions, confirming the major role of this gene in the regulation of neuroinflammation.

Very interestingly, the study showed Gcm2 protein expression in active lesions multiple sclerosis in humans, lesions in which significant inflammation is observed.

 

New therapeutic avenues

From a biological point of view, those results demonstrate that the expression of Gcm2 by microglial/macrophage cells favors their transition to an anti-inflammatory state which benefits to lesion repair.

Gcm is a transcription factor, i.e. a protein necessary for the initiation or regulation of gene transcription. Its expression leads to a cascade of biological reactions, known as a signaling pathway, which in turn involves several other proteins. Given the strong potential of transcription factors in coordinating the expression of several genes and the small number of known transcription factors with a similar function, the results of this work represent a major contribution to the understanding of the molecular mechanisms controlling the inflammatory response.

It also pave the way to new therapeutic targets studies for diseases where the inflammatory response must be contained, such as multiple sclerosis or other neurodegenerative diseases.

Source: Pavlidaki A., Panic R et al. Cell Reports 41, 3, 111506, October 18, 2022

https://doi.org/10.1016/j.celrep.2022.111506

Scientific teams

Team “Myelin plasticity and regeneration”
Team leader
Brahim NAIT OUMESMAR PhD, DR2, INSERM
Violetta ZUJOVIC PhD, CR1, INSERM
Repair Main domain: Cellular & molecular neurosciences Subdomain : Clinical & translational neurosciences Brahim NAIT OUMESMAR & Violetta ZUJOVIC’s team aims at providing better insight into the mechanisms of myelin plasticity and regeneration. Compelling evidences indicate that oligodendrocyte progenitor cells (OPCs) sense neuronal activity and immune cells signaling, highlighting the importance of these crosstalk’s in (re)-myelination. Therefore, our research project will rely on three major aims to decipher:
  • The role of i)neuronal activity and ii) immune cells in oligodendrocyte differentiation, regeneration and myelin repair, unraveling their relevance in human oligodendrocyte differentiation;
  • To develop innovative tools to identify and assess the therapeutic value of new pro-myelinating compounds.
Read more